144 related articles for article (PubMed ID: 4358224)
1. Potential antidiabetic agents. Pyrazolo(3,4-b)pyridines.
Höhn H; Polacek I; Schulze E
J Med Chem; 1973 Dec; 16(12):1340-6. PubMed ID: 4358224
[No Abstract] [Full Text] [Related]
2. 1-Ethyl-4-(isopropylidenehydrazino)-1H-pyrazolo-(3,4-b)-pyridine-5-carboxylic acid, ethyl ester, hydrochloride (SQ 20009)--a potent new inhibitor of cyclic 3',5'-nucleotide phosphodiesterases.
Chasin M; Harris DN; Phillips MB; Hess SM
Biochem Pharmacol; 1972 Sep; 21(18):2443-50. PubMed ID: 4345859
[No Abstract] [Full Text] [Related]
3. Synthesis and antidiabetic activity of some sulfonylurea derivatives of 3,5-disubstituted pyrazoles.
Soliman R; Mokhtar H; Mohamed HF
J Pharm Sci; 1983 Sep; 72(9):999-1004. PubMed ID: 6631713
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and antidiabetic activity of some sulfonylurea derivatives of 3,4,5-trisubstituted pyrazoles.
Soliman R; Mokhtar H; Mohamed HF
J Pharm Sci; 1983 Sep; 72(9):1004-7. PubMed ID: 6631680
[TBL] [Abstract][Full Text] [Related]
5. Preparation and antidiabetic activity of some sulfonylurea derivatives of 3,5-disubstituted pyrazoles.
Soliman R
J Med Chem; 1979 Mar; 22(3):321-5. PubMed ID: 423216
[TBL] [Abstract][Full Text] [Related]
6. Preparation and antidiabetic activity of new substituted 3,5-diarylpyrazolesulfonylurea derivatives.
Soliman R; Feid-Allah HM; El Sadany SK; Mohamed HF
J Pharm Sci; 1981 Jun; 70(6):606-10. PubMed ID: 6788935
[No Abstract] [Full Text] [Related]
7. Preparation and antidiabetic activity of new 3-methyl-5-phenylpyrazolesulfonylurea derivatives.
Soliman R; Feid-Allah HM
J Pharm Sci; 1981 Jun; 70(6):602-5. PubMed ID: 6788934
[No Abstract] [Full Text] [Related]
8. [Inhibition of cyclic 3',5'-nucleotide phosphodiesterase by glypentide and other oral antidiabetic agents (author's transl)].
García-Rafanell J; Morell-Mestre J
Rev Esp Fisiol; 1974 Dec; 30(4):277-81. PubMed ID: 4376253
[No Abstract] [Full Text] [Related]
9. Antidiabetic effect of novel benzenesulfonylureas as PPAR-γ agonists and their anticancer effect.
Kharbanda C; Alam MS; Hamid H; Javed K; Dhulap A; Bano S; Ali Y
Bioorg Med Chem Lett; 2015 Oct; 25(20):4601-5. PubMed ID: 26384286
[TBL] [Abstract][Full Text] [Related]
10. Effects of some isoquinoline compounds and certain derivatives on brain phosphodiesterase activity.
Furlanut M; Carpenedo F; Ferrari M
Biochem Pharmacol; 1973 Oct; 22(20):2642-4. PubMed ID: 4357892
[No Abstract] [Full Text] [Related]
11. Synthesis and SAR study of novel tricyclic pyrazoles as potent phosphodiesterase 10A inhibitors.
Dore A; Asproni B; Scampuddu A; Pinna GA; Christoffersen CT; Langgård M; Kehler J
Eur J Med Chem; 2014 Sep; 84():181-93. PubMed ID: 25016376
[TBL] [Abstract][Full Text] [Related]
12. [Derivatives of pyrazole-l-carboxylic acid. VII. Synthesis and hypoglycemic properties of various N-(4-[2-(alkyl-2-pyrazoline-1-carbonamido)-ethyl]-benzenesulfonyl)-N'-cyclohexylurea].
Brzozowski Z; Magiełka S; Wójcikowski C
Acta Pol Pharm; 1983; 40(2):134-8. PubMed ID: 6659996
[No Abstract] [Full Text] [Related]
13. Synthesis and hypoglycemic evaluation of substituted pyrazole-4-carboxylic acids.
Cottineau B; Toto P; Marot C; Pipaud A; Chenault J
Bioorg Med Chem Lett; 2002 Aug; 12(16):2105-8. PubMed ID: 12127514
[TBL] [Abstract][Full Text] [Related]
14. Effect of cyclic nucleotides on activity of cyclic 3',5'-adenosine monophosphate phosphodiesterase.
Harris DN; Chasin M; Phillips MB; Goldenberg H; Samaniego S; Hess SM
Biochem Pharmacol; 1973 Jan; 22(2):221-8. PubMed ID: 4357795
[No Abstract] [Full Text] [Related]
15. Sulfonylureas and the heart.
Levey GS; Lasseter KC; Palmer RF
Annu Rev Med; 1974; 25():69-74. PubMed ID: 4363211
[No Abstract] [Full Text] [Related]
16. Inhibitory and activators of cyclic nucleotide phosphodiesterase.
Chasin M; Harris DN
Adv Cyclic Nucleotide Res; 1976; 7():225-64. PubMed ID: 188316
[No Abstract] [Full Text] [Related]
17. Effect of glucagon, dibutyryl adenosine 3',5'-cyclic monophosphate and phosphodiesterase inhibitors on rat liver phosphorylase activity and adenosine 3',5'-cyclic monophosphate levels.
Ingebretsen C; Clark JF; Allen DO; Ashmore J
Biochem Pharmacol; 1974 Aug; 23(15):2139-46. PubMed ID: 4369954
[No Abstract] [Full Text] [Related]
18. New oral antidiabetic drugs. 3.
Ambrogi V; Bloch K; Daturi S; Logemann W; Parenti MA; Tommasini R
Arzneimittelforschung; 1972 Mar; 22(3):542-4. PubMed ID: 5067927
[No Abstract] [Full Text] [Related]
19. New oral antidiabetic drugs. Synthesis and structure-activity relationships.
Francia E; Marin A; Verdejo F; Sanchez MS; Morell J
Boll Chim Farm; 1975 Jul; 114(7):379-92. PubMed ID: 1164447
[No Abstract] [Full Text] [Related]
20. [New hypoglycemic benzenesulfonamido-pyrimidines N-substituted 4- N-(2-pyrimidinyl) sulfonyl--phenylacetamides].
Gutsche K; Schröder E; Rufer C; Loge O
Arzneimittelforschung; 1974 Jul; 24(7):1028-39. PubMed ID: 4408077
[No Abstract] [Full Text] [Related]
[Next] [New Search]
